Teladoc Health (NYSE:TDOC) Updates FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -1.100–0.700 for the period, compared to the consensus estimate of -0.870. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q1 2026 guidance to -0.450–0.350 EPS.

Teladoc Health Stock Performance

NYSE TDOC traded up $0.12 on Wednesday, reaching $4.66. 6,087,236 shares of the stock were exchanged, compared to its average volume of 6,532,484. The company’s 50-day simple moving average is $6.11 and its two-hundred day simple moving average is $7.24. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $826.12 million, a PE ratio of -3.64 and a beta of 2.12. Teladoc Health has a one year low of $4.40 and a one year high of $11.55.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts expect that Teladoc Health will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TDOC shares. Bank of America reduced their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 25th. BMO Capital Markets began coverage on Teladoc Health in a research note on Thursday, November 13th. They set a “market perform” rating and a $8.00 price target for the company. Barclays began coverage on Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective on the stock. Citigroup reduced their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Teladoc Health presently has an average rating of “Hold” and an average target price of $9.12.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 17,138 shares of Teladoc Health stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Adam C. Vandervoort sold 5,720 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $42,842.80. Following the completion of the transaction, the insider directly owned 80,732 shares in the company, valued at approximately $604,682.68. This trade represents a 6.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 33,288 shares of company stock valued at $251,684 over the last ninety days. Company insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several institutional investors have recently made changes to their positions in TDOC. Corient Private Wealth LLC raised its stake in Teladoc Health by 236.6% in the 4th quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock worth $264,000 after acquiring an additional 26,494 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of Teladoc Health by 38.6% in the fourth quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock worth $1,157,000 after purchasing an additional 46,090 shares during the last quarter. Empowered Funds LLC raised its stake in shares of Teladoc Health by 1.9% in the fourth quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock worth $5,196,000 after purchasing an additional 14,029 shares during the last quarter. Voloridge Investment Management LLC boosted its position in Teladoc Health by 42.8% in the fourth quarter. Voloridge Investment Management LLC now owns 997,427 shares of the health services provider’s stock valued at $6,982,000 after buying an additional 299,086 shares during the last quarter. Finally, Polymer Capital Management US LLC increased its holdings in Teladoc Health by 32.0% in the 4th quarter. Polymer Capital Management US LLC now owns 22,443 shares of the health services provider’s stock worth $157,000 after buying an additional 5,443 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.